Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

NCT05992584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib, sintilimab plus SIRT

Sponsor

Second Affiliated Hospital of Guangzhou Medical University